Scarica l'app Stockscreener
1.51
1.31%
-0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NMRA Giù?
Forum
Previsione
Precedente Chiudi:
$1.53
Aprire:
$1.58
Volume 24 ore:
2.20M
Relative Volume:
1.12
Capitalizzazione di mercato:
$279.78M
Reddito:
-
Utile/perdita netta:
$-222.39M
Rapporto P/E:
-1.1381
EPS:
-1.3268
Flusso di cassa netto:
$-193.40M
1 W Prestazione:
-15.17%
1M Prestazione:
-14.69%
6M Prestazione:
-12.21%
1 anno Prestazione:
+93.59%
Intervallo 1D:
$1.43
$1.63
Intervallo di 1 settimana:
$0.8302
$1.84
Portata 52W:
$0.7158
$3.65
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Nome
Neumora Therapeutics Inc
Settore
Industria
Telefono
(857) 760-0900
Indirizzo
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.51 | 279.78M | 0 | -222.39M | -193.40M | -1.3268 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-17 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2026-01-12 | Iniziato | Leerink Partners | Outperform |
| 2025-12-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-27 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-09-16 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-04-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-03-10 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-07 | Downgrade | Stifel | Buy → Hold |
| 2025-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Hold |
| 2023-10-10 | Iniziato | BofA Securities | Buy |
| 2023-10-10 | Iniziato | Guggenheim | Buy |
| 2023-10-10 | Iniziato | JP Morgan | Overweight |
| 2023-10-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-10 | Iniziato | Stifel | Buy |
| 2023-10-10 | Iniziato | William Blair | Outperform |
Mostra tutto
Neumora Therapeutics Inc Borsa (NMRA) Ultime notizie
Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds - The National Law Review
Neumora Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Pinto Joshua - Moomoo
Neumora Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Neumora Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer BERNS PAUL L - Moomoo
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud - Business Wire
Rx Rundown: Sanofi, Neumora Therapeutics, Uniqure and more - Medical Marketing and Media
Neumora Therapeutics Inc (NMRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neumora Therapeutics Inc (NMRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neumora Therapeutics Inc (NMRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Robbins LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors - GuruFocus
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials - Stocktwits
Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression Data - Yahoo Finance
NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations – Company AnnouncementFT.com - Financial Times
Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA) - PR Newswire
Neumora Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics, Inc. (NMRA) - ACCESS Newswire
Neumora stock plunges 49% after late-stage depression drug failure - MSN
Kappa Opioid Antidepressant Navacaprant Goes 0-for-3 in Phase 3: Neumora Cuts 35% of Staff - Tech Times
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Three pivotal MDD trial failures for Neumora lead to staffing cuts - Yahoo Finance
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure - The Globe and Mail
Neumora scraps depression drug, cuts 35% of staff, refocuses pipeline - Stock Titan
NMRA Maintains Buy Rating by Needham -- Price Target Lowered to $5.00 - GuruFocus
Neumora Pivots To Broader Pipeline After Navacaprant Fails In MDD - Citeline News & Insights
W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Needham cuts Neumora stock price target on navacaprant discontinuation - Investing.com
Needham cuts Neumora stock price target on navacaprant discontinuation By Investing.com - Investing.com Canada
Neumora stock price target cut to $7 on failed trial, H.C. Wainwright maintains buy - Investing.com Canada
Neumora Therapeutics Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Neumora bins depression drug after Phase III failures - The Pharma Letter
Neumora depression drug fails; EnGene to cut 50% of staff - Yahoo Finance
Layoff Tracker: Neumora, enGene cut staff in cost-saving initiatives - BioSpace
NMRA stock on track for worst day in 1.5 years — Neumora Therapeutics' lead depression drug fails late stage trials - MSN
Neumora ends depression drug programme and announces workforce reduction (NMRA) - MSN
William Blair Maintains Neumora Therapeutics(NMRA.US) With Buy Rating - Moomoo
Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail - Benzinga
NMRA INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Neumora Therapeutics, Inc. - GlobeNewswire
Neumora plummets as phase 3 navacaprant data misses key goal - MSN
Neumora shifts focus to Alzheimer's and obesity drugs after navacaprant setback - The Business Journals
Neumora scraps depression drug development after repeated trial failures - Reuters
Neumora discards depression asset, lays off staffers after pair of late-stage flops - BioSpace
Neumora Therapeutics Discontinues Navacaprant After Phase 3 Failure, Advances Alzheimer’s and Schizophrenia Pipeline - Minichart
Neumora stock plunges after phase 3 trial failure By Investing.com - Investing.com Nigeria
Neumora discontinues navacaprant after phase 3 trial failures By Investing.com - Investing.com Australia
Navacaprant fails Phase 3 trials; Neumora halts its development, focusing on other drug candidates. - Pluang
Neumora Ends Depression Drug Programme and Announces Workforce Reduction (NMRA) - Yahoo Finance
Neumora pulls plug off depression drug after trial failures, cut jobs - Investing.com Canada
Neumora Ends Navacaprant After Phase 3 Trial Failure - TipRanks
Neumora discontinues navacaprant after phase 3 trial failures - Investing.com
Neumora Therapeutics scraps depression drug after two late-stage trial failures - TradingView
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update - The Manila Times
CRNX,NMRA Volatility & Greeks - Finviz
Neumora Therapeutics Inc Azioni (NMRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):